Last reviewed 2026-04-23 · How we verify

FEC75

FEC75 is a chemotherapy regimen that combines 5-fluorouracil, epirubicin, and cyclophosphamide to treat breast cancer.

FEC75 is a chemotherapy regimen that combines 5-fluorouracil, epirubicin, and cyclophosphamide to treat breast cancer. Used for Adjuvant treatment of node-positive breast cancer, Treatment of metastatic breast cancer.

At a glance

Mechanism of action

This regimen works by inhibiting DNA synthesis and function, causing cell death in rapidly dividing cancer cells. The combination of these three drugs targets different stages of the cell cycle, increasing the effectiveness of the treatment. However, this also increases the risk of side effects.

Approved indications

• Adjuvant treatment of node-positive breast cancer
• Treatment of metastatic breast cancer

Common side effects

• Neutropenia
• Thrombocytopenia
• Anemia
• Nausea and vomiting
• Diarrhea
• Fatigue

Key clinical trials

• Central Catheters Used for Chemotherapy in Women With Breast Cancer (NA)
• Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery (PHASE3)
• Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy. (PHASE2)
• Phase II Neoadjuvant in Inflammatory Breast Cancer (PHASE2)
• Dose Density FU 75 and FU 90 as Adjuvant Therapy for Early Breast Cancer (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• FEC75 CI brief — competitive landscape report
• FEC75 updates RSS · CI watch RSS
• GlaxoSmithKline portfolio CI